Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages

Journal of Antimicrobial Chemotherapy

Volumn 41, Issue 1, 1998, Pages 77-83

  Sato, K ^a   Akaki, T ^a   Tomioka, H ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; LEVOFLOXACIN; RIFALAZIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; CULTURE MEDIUM; DRUG POTENCY; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; FEMALE; LUNG; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM; OFLOXACIN; PHAGOCYTOSIS; RIFAMYCINS; TUBERCULOSIS;

EID: 0031931286     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/41.1.77     Document Type: Article

References (18)

1. Young, L. S. (1996). Mycobacterial infections in immuno-compromised patients. Current Opinion in Infectious Diseases 9, 240-5.
2. Benson, C. A. (1996). Treatment of disseminated Mycobacterium avium complex disease: a clinician's prespective. Research in Microbiology 147, 16-24.
3. Saito, H., Tomioka, H., Sato, K., Emori, M., Yamane, T., Yamashita, K. et al. (1991). In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrobial Agents and Chemotherapy 35, 542-7.
4. Tomioka, H., Saito, H., Fujii, K., Sato, K. & Hidaka, T. (1993). In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric method. Antimicrobial Agents and Chemotherapy 37, 67-70.
5. Inderlied, C. B., Barbara-Burnham, L., Wu, M., Young, L. S. & Bermudez, L. E. M. (1994). Activities of the benzoxazinorifamycin KRM-1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages. Antimicrobial Agents and Chemotherapy 38, 1838-43.
6. Saito, H., Tomioka, H., Sato, K. & Dekio, S. (1994). In vitro and in vivo activities of clarithromycin against the Mycobacterium avium complex. International Journal of Antimicrobial Agents 4, 175-81.
7. Fattorini, L., Li, B., Piersimoni, C., Tortoli, E., Xiao, Y., Santoro, C. et al. (1995). In vitro and ex vivo activities of antimicrobial agents used in combination with clarithromycin, with or without amikacin, against Mycobacterium avium. Antimicrobial Agents and Chemotherapy 39, 680-5.
8. Mor, N., Simon, B. & Heifets, L. (1996). Bacteriostatic and bactericidal activities of benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis and Mycobacterium avium in human macrophages. Antimicrobial Agents and Chemotherapy 40, 1482-5.
9. Tomioka, H., Saito, H., Sato, K., Yamane, T., Yamashita, K., Hosoe, K. et al. (1992). Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrobial Agents and Chemotherapy 36, 387-93.
10. Bermudez, L. E., Kolonoski, P., Young, L. S. & Inderlied, C. B. (1994). Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. Antimicrobial Agents and Chemotherapy 38, 1844-8.
11. Saito, H., Tomioka, H., Sato, K., Kawahara, S., Hidaka, T. & Dekio, S. (1995). Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. Tubercle and Lung Disease 76, 51-8.
12. Heifets, L. (1996). Susceptibility testing of Mycobacterium avium complex isolates. Antimicrobial Agents and Chemotherapy 40, 1759-67.
13. Heifets, L. B. (1996). Clarithromycin against Mycobacterium avium complex infections. Tubercle and Lung Disease 77, 19-26.
14. Saito, H., Sato, K., Tomioka, H. & Dekio, S. (1995). In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tubercle and Lung Disease 76, 377-80.
15. Ji, B., Lounis, N., Truffot-Pernot, C. & Grosset, J. (1995). In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 39, 1341-4.
16. Yajko, D. M., Nassos, P. S. & Hadley, W. K. (1987). Broth microdilution testing of susceptibilities to 30 antimicrobial agents of Mycobacterium avium strains from patients with acquired immune deficiency syndrome. Antimicrobial Agents and Chemotherapy 31, 1579-84.
17. Bermudez, L. E., Inderlied, C. B., Kolonoski, P., Wu, M., Barbara-Burnham, L. & Young, L. S. (1996). Activities by Bay Y3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. Antimicrobial Agents and Chemotherapy 40, 546-51.
18. Mehta, P. K., King, C. H., White, E. H., Murtagh, J. J. & Quinn, F. D. (1996). Comparison of in vitro models for the study of Mycobacterium tuberculosis invasion and intracellular replication. Infection and Immunity 64, 2673-9.